CRISPR Therapeutics and MaxCyte expand clinical and commercial license agreement
CRISPR Therapeutics and MaxCyte announced the expansion of their existing relationship by entering into a non-exclusive commercial license agreement that will allow CRISPR Therapeutics to deploy MaxCyte’s Flow Electroporation® Technology to develop CRISPR/Cas9-based therapies in immuno-oncology. November 09, 2018